EMVision Medical Devices Ltd engages in the research, development, and commercialization of neurodiagnostic technology for stroke diagnosis and monitoring, and other medical imaging needs in Australia.
Show moreShow less
It offers non-invasive brain scanners, including emu Brain Scanner, a bedside device; and First Responder Brain Scanner, a device embedded in standard road and air ambulances to deliver pre-hospital stroke diagnosis and care to patients.
The company was incorporated in 2017 and is based in Macquarie Park, Australia.
Quality Score breakdown
Overall quality29/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability1
How much profit the company makes from its sales and capital
Quality Growth20
Are margins and returns getting better?
Cashflow6
Do the profits arrive as real cash?
Financial strength97
Debt, balance sheet and risk of trouble
Investment33
Does it invest with discipline instead of growing at any price?
Low Volatility49
How calm the share price moves, does not count
Price momentum23
Price momentum of the last 3 to 12 months, does not count
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−55.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+38.8%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.4%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−354.3% (2020) → −160.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Emvision Medical Devices Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 323 stocks
Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score29 · Bottom 25%
Profitability
Return on assets−36.1% · Bottom 25%
Net margin (12 months)−99.5% · Bottom 25%
Operating margin (12 months)−100.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)187.5% · Top 25%
Balance sheet
Debt / equity0.17× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
Emvision Medical Devices Ltd has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Emvision Medical Devices Ltd (EMV)?
Emvision Medical Devices Ltd reported trailing-twelve-month revenue of about A$8.4M (latest available figure, as of Oct 30, 2026).
How solid is the balance sheet of Emvision Medical Devices Ltd (EMV)?
Balance-sheet figures for Emvision Medical Devices Ltd (as of Oct 30, 2026): return on equity −66.4%, debt of 0.17 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
Which stocks are comparable to Emvision Medical Devices Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
What is the share price of Emvision Medical Devices Ltd (EMV)?
The closing price on Nov 4, 2026 was A$1.46. We carry closing prices from our data provider, not a live tick.
Key figures of Emvision Medical Devices Ltd
How large is the market capitalisation of Emvision Medical Devices Ltd (EMV)?
The market capitalisation of Emvision Medical Devices Ltd is A$136M (≈ $94.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Emvision Medical Devices Ltd (EMV)?
The price-to-sales ratio of Emvision Medical Devices Ltd is 16.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Emvision Medical Devices Ltd (EMV)?
Earnings per share at Emvision Medical Devices Ltd are A$−0.0900. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Emvision Medical Devices Ltd (EMV)?
The net margin of Emvision Medical Devices Ltd is −99.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Emvision Medical Devices Ltd (EMV)?
The return on equity (ROE) of Emvision Medical Devices Ltd is −66.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Emvision Medical Devices Ltd (EMV)?
On an EBIT basis the return on assets of Emvision Medical Devices Ltd is −70.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Emvision Medical Devices Ltd (EMV)?
The operating margin of Emvision Medical Devices Ltd is −101% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Emvision Medical Devices Ltd (EMV)?
Revenue at Emvision Medical Devices Ltd is growing +188% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Emvision Medical Devices Ltd (EMV) generate?
The free cash flow of Emvision Medical Devices Ltd is −A$6.4M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Emvision Medical Devices Ltd (EMV) hold?
Emvision Medical Devices Ltd holds more cash than debt, A$13.7M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Emvision Medical Devices Ltd in the live analysis
One click puts Emvision Medical Devices Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Oct 30, 2026